INDIANAPOLIS, May 5, 2026
Eli Lilly and Company has reported new long-term clinical data demonstrating that Omvoh® (mirikizumab-mrkz) achieved durable disease clearance in patients with moderately to severely active ulcerative colitis (UC) over a period of four years, marking a significant milestone in immunology and gastrointestinal therapeutics. The findings, presented at a major scientific congress, position Omvoh as the first and only IL-23p19 inhibitor to demonstrate sustained disease clearance over this duration, setting a new benchmark in chronic inflammatory bowel disease management.
Lilly Advances Long-Term Disease Clearance in UC
The results from the LUCENT-3 open-label extension study showed that 63.5% of patients who achieved disease clearance at one year maintained it through four years of continuous treatment, highlighting the long-term efficacy of Omvoh. Disease clearance is defined as the simultaneous achievement of symptomatic remission, endoscopic healing, and histologic remission, representing a high clinical standard beyond symptom control.
This comprehensive endpoint reflects the ability of Omvoh to not only manage symptoms but also address underlying disease pathology. Even under more stringent criteria, including endoscopic normalization, over 61% of patients sustained remission, reinforcing the therapy’s potential to alter disease progression and improve long-term outcomes in ulcerative colitis.
Targeting IL-23 Pathway for Sustained Therapeutic Impact
Advertisement
Omvoh is a selective IL-23p19 antagonist, targeting a key inflammatory pathway implicated in inflammatory bowel disease (IBD). By inhibiting the IL-23 pathway, the therapy reduces chronic inflammation and supports mucosal healing, which is critical for achieving durable remission.
The clinical program includes Phase 3 trials (LUCENT-1 and LUCENT-2), which demonstrated significant efficacy and safety in both biologic-naïve patients and those with prior treatment failure, followed by long-term evaluation in LUCENT-3. The consistency of results across these studies underscores the robust clinical profile and sustained therapeutic benefit of Omvoh.
Importantly, the long-term safety profile remained consistent with previous findings, with no new safety signals identified, supporting the continued use of Omvoh as a reliable treatment option for chronic disease management. The most common adverse events included upper respiratory tract infections, injection site reactions, and mild systemic effects, aligning with known safety data.
Clinical and Healthcare Impact of Durable Remission
The ability to achieve and sustain disease clearance over multiple years has significant implications for patients and healthcare systems. In real-world settings, disease clearance is associated with reduced hospitalizations, lower surgical intervention rates, and improved quality of life.
The data also highlight the potential of Omvoh to redefine treatment goals in ulcerative colitis, shifting from symptom management to deep and sustained remission. This aligns with evolving clinical guidelines that emphasize long-term disease control and prevention of complications.
Additionally, Omvoh has received regulatory approvals in multiple regions for the treatment of ulcerative colitis and Crohn’s disease, further supporting its role as a key biologic therapy in gastroenterology. Ongoing studies are exploring combination therapies and expanded indications, including pediatric populations and metabolic comorbidities, indicating a broad and evolving clinical development strategy.
Implications for Biopharma Innovation
The success of Omvoh reflects broader advancements in biopharmaceutical innovation, particularly in the development of targeted biologics for immune-mediated diseases. The ability to demonstrate long-term outcomes such as disease clearance underscores the importance of precision-targeted therapies and robust clinical trial design in modern drug development.
As healthcare systems increasingly focus on value-based care and long-term patient outcomes, therapies that deliver sustained remission are expected to play a critical role in reducing disease burden and improving healthcare efficiency. Lilly’s continued investment in immunology research further reinforces its leadership in next-generation biologic therapies.
Source: Eli Lilly press release
